|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT02227043 |
|
Date of registration:
|
22/08/2014 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Study Of Weight Development Over Time
SOWOT |
|
Scientific title:
|
Study Of Adipose Tissue Function and Weight Development Over Time |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
105 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02227043 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Sweden
| | | | | | | |
|
Contacts
|
|
Name:
|
Mikael Ryden, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Karolinska Institutet |
|
|
Name:
|
Peter Arner, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Karolinska Institutet |
|
|
Name:
|
Daniel P Andersson, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Karolinska Institutet |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Participated in previous examination at our lab at least 7 years ago.
- No blood samples or adipose samples saved from last examination
Exclusion Criteria:
- Decline to participate after invitation.
- Serious illness or mental disorder.
- Warfarin or other new oral anticoagulant that increase risk of bleeding.
Age minimum:
24 Years
Age maximum:
90 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Insulin Resistance
|
|
Weight Reduction
|
|
Weight Gain
|
|
Obesity
|
|
Primary Outcome(s)
|
|
Weight development and correlation to lipogenesis
[Time Frame: 2014 to 2024, up to 10 years]
|
|
Weight development and correlation to lipolysis
[Time Frame: 2014 to 2024, up to 10 years]
|
|
Weight development over time and correlation to adipose morphology
[Time Frame: from 2014 up to 2024, up to 10 years]
|
|
Secondary Outcome(s)
|
|
adipose morphology and development of fat mass
[Time Frame: 2014 to 2024, up to 10 years]
|
|
adipose tissue morphology development and insulin sensitivity
[Time Frame: 2014 to 2024, up to 10 years]
|
|
adipose morphology and changes in fat mass
[Time Frame: 2014 to 2024, up to 10 years]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|